By Class: 
   - Monoclonal antibody
   - Bispecific antibody
   - Antibody-drug conjugates 
   - Radioimmunotherapy
   - Immune mediated | PD-1 antibody
   - Cytotoxic

Targeted  
   - Epigenetic agents
   - Apoptosis - activating programmed cell death  
   - Kinase inhibitors (e.g., ibrutinib) | mTOR | Other
   - Tumor suppressor gene

Dose - the importance of getting it right
 

Agents with recent encouraging clinical reports

	Abexinostat (PCI-24781)  (pan HDAC inhibitor) Find trials
	ABT-199 / Venetoclax  (activating apoptosis) Find trials
	Adcetris ®  SGN-35 / brentuximab vedotin  (antibody-drug conjugate: anti-cd30 + antitubulin)  Find trials
	Belinostat PXD101 (epigenetic - recent approval) Find trials
	btk / B-cell receptor pathway Ibrutinib (all - recent approval for CLL; inhibiting btk - on b-cell receptor pathway) Find trials Ibrutinib for Lymphoma only  Find Trials Acalabrutinib (ACP-196)  Find trials ASH15 Report
	CAR T-cd19 cell therapy (adoptive immunotherapy)  Find trials
	GA-101 (Obinutuzumab), next generation cd20 antibody  Find trials
	INCB050465 (Pki3k-delta inhibitor)  Find Trials
	Selinexor Oral Selective Inhibitor of Nuclear Export (SINE) Find trials
	Lenalidomide (immune modulation and direct activity)  Find trials
	Monalizumab (CD94/NKG2A checkpoint mab) for| CLL OR lymphoma Find Trials
	PI3k Delta Inhibitors Idelalisib GS-1101 formerly CAL101 (inhibiting b-cell receptor pathway)  Find trials (FDA-approved) TGR-1202 (PI3k Delta Inhibitor) Find Trials (Reports suggest better-tolerated version) TGR-1202 + Ibrutinib in Patients With Select B-Cell lymphoma http://1.usa.gov/1zvYgmu TGR-1202 (PI3K Delta Inhibitor) With Brentuximab Vedotin for Hodgkin's Lymphoma
	PD1/L antibodies (immune checkpoint antibodies)  Find trials  (updated)
	YM155 (Survivin inhibitor)  Find Trials >
	Zevalin ® anti-CD20 + Yttrium 90 (Ibritumomab tiuxetan)  (radioimmunotherapy) Trials  Find trials
	Vidaza ®  5-Azacytidine (epigenetic - activating or shutting off genes) Find trials

2016, June: Advocate's perspective: rationale for continued study of Radioimmunotherapy

What's New

Abexinostat| Lirilumab | 4-1BB antibody | CC-122 | CPI-0610| Daratumumab (Mab) | denintuzumab mafodotin| Mocetinostat  (HDAC)| ONC201 |  XmAb5574 / MOR00208 (cd19 Mab)  | MEDI-570 (anti-ICOS) | IPH2201 |JNJ-64052781 | IMMU-114 | Pembrolizumab | IMO-8400 | RP6530 | Buparlisib

	4-1BB antibody - NKT cell-targeted vaccination given with 4-1BB  leads to CD8 T cell immunity against B cell lymphoma. http://1.usa.gov/1MuMY4c  *PF-05082566 (anti-4-1BB antibody) As A Single Agent and With Rituximab -  ClinicalTrials.gov | Find Trials
	Abexinostat A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor Abexinostat in relapsed/refractory lymphoma. - PubMed | Full report | Results | Find trials
	ABT-199  (activating apoptosis - programmed cell death - through bcl2 pathway)  Find trials FDA Grants Breakthrough Therapy Designation to Venetoclax (ABT-199) for Patients with Relapsed/Refractory CLL with 17P Deletion http://bit.ly/1cmRGoX
	Acalabrutinib (ACP-196) (inhibits btk / B-cell receptor pathway - an overactive pathway in b-cell lymphomas)  Find trials  ASH15 Report ACP 196 (next gen BTK inhibitor) in Mantle Cell Lymphoma  http://1.usa.gov/1w6GhkC
	AGS67E (anti-cd37 antibody-drug conjugate)  Find Trials A first in human report: anti-CD37 antibody-drug conjugate AGS67E in #lymphoma | 2016 ASCO http://bit.ly/25cvcQG
	ASN002 (Syk/Jak inhibitor) Find trials
	Atezolizumab / MPDL3280A (is a pd1-antibody). An immune checkpoint inhibitor that blocks the breaks on the immune system Studies testing Atezolizumab - List Results - ClinicalTrials.gov Find Trials  Testing Atezolizumab (pd-1 antibody) with Obinutuzumab (anti-cd20) with Lenalidomide in Relapsed / Refractory Follicular Lymphoma Trial of Interest A related article: New on Cancer Currents: Checking in on Cancer Checkpoint Inhibitors http://1.usa.gov/1OoFtuB
	BET Inhibitor CPI-0610 Well Tolerated and active in Diffuse Large B-Cell and Follicular Lymphoma Report Studies testing CPI-0610 (BET protein inhibitor) in lymphoma or CLL Find trials
	BKM120 (PI3K inhibitor - BCR pathway) Find trials  >
	Brentuximab Vedotin -  for t-cell lymphoma - studies testing ClinicalTrials.gov Find Trials The ASCO Post Brentuximab Vedotin Shows Antitumor Activity in Patients With Relapsed Peripheral T-Cell Lymphoma http://bit.ly/1G6asLx  Among the 14 patients achieving an objective response, 8 had complete responses, including 5 patients with angioimmunoblastic T-cell lymphoma. At the time of the study report, the median duration of response for all patients was 7.6 months, with five responding patients remaining in follow-up and five on therapy. This will lead to a study testing this agent as a part of first line therapy for this very challenging indication.  Query to locate such studies above.
	Buparlisib (oral inhibitor of the pan-class class I PIK3 pathway) Find Trials
	CC-122 (immune-modulating) for lymphoma or CLL - ClinicalTrials.gov http://1.usa.gov/1Pb3Ly7  CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBC Lymphoma http://1.usa.gov/1Q25Vz2
	Copanlisib / BAY 80-6946  (PI3Kα/β inhibitor given by vein) Find Trials
	Testing CUDC-907 (dual inhibitor of PI3K and HDAC) +/- Rituximab in RR MYC-Altered DLBCL http://1.usa.gov/1o4bz9q  Report: phase I oral CUDC-907, a dual inhibitor of PI3K and HDAC, in R/R lymphoma or myeloma http://bit.ly/1TbyNWU
	Denintuzumab mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for DLBC #Lymphoma http://ClinicalTrials.gov http://1.usa.gov/20gF8DN   Find Trials Key eligibility: Pathologically confirmed diagnosis of relapsed or refractory diffuse large B-cell lymphoma (DLBCL; including de novo and transformed DLBCL) or Grade 3b follicular lymphoma "SGN-CD19A is an ADC targeting CD19, a protein expressed uniformly on almost all B-cell malignancies. The ADC is designed to be stable in the bloodstream and release its cytotoxic agent upon internalization into CD19-expressing cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity." * Efficacy & safety report for SGN-CD19A Antibody-Drug Conjugate (denintuzumab mafodotin) at ASH http://yhoo.it/1New9xx
	EZH2 inhibitors (epigenetic)   Find Trials Related article: New investigational compound shows promise against melanoma, lymphoma http://bit.ly/24ufhgi
	IMO-8400 (TLR inhibitor) in lymphoma with MyD88L265P Mutation ClinicalTrials.gov Find Trials
	IMMU-114 (anti–HLA-DR Mab) in Relapsed or Refractory non-Hodgkin Lymphoma and CLL http://1.usa.gov/1OsAK0o  Find Trials Background: anti–HLA-DR humanized monoclonal antibody, IMMU-114, mediated bu hyperactivation of ERK and JNK MAP kinase pathways http://1.usa.gov/1OvkgTz
	IPH2201 (checkpoint inhibitor) With Ibrutinib for Relapse or Refractory CLL http://1.usa.gov/1QK56sM Background: checkpoint inhibitor - IPH2201: first-in-class anti-NKG2A mAb | Innate Pharma http://bit.ly/1O0BckD IPH2201 (NK cell checkpoint inhibitor) Find Trials Phase 1 dose-escalation study of lirilumab (IPH2102, BMS-986015, LIRI), a fully human anti-KIR monoclonal antibody in patients with various hematologic (HEM) or solid (SOL) malignancies http://bit.ly/1TFc9Fl "The blockade of KIR by LIRI fosters the activation of NK cells, selectively enhancing the cytotoxicity of NK cells against tumor cells without affecting healthy tissues."
	JNJ-64052781 (Humanized CD19 x CD3 Dual-Affinity Re-Targeting Protein)  Find Trials
	Lirilumab (NK-cell agonist) in lymphoma or CLL Find Trials Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Open Protocol Background: Anti-KIR antibody (Lirilumab)  enhancement of anti-lymphoma activity of natural killer cells with anti-CD20 antibodies http://1.usa.gov/1R4UJ5w
	MEDI-570 (anti-ICOS) in Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma http://1.usa.gov/1MwTcCu Related background: B Cells in Health and Disease – Leveraging Flow Cytometry to Evaluate Disease Phenotype and the Impact of Treatment with Immunomodulatory Therapeutics http://bit.ly/1EAIe8L
	MLN9708 (Ixazomib, GATA-3 inhibitor) for Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Trial of interest MLN9708 (Ixazomib, GATA-3 inhibitor) for Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas http://1.usa.gov/1iEFBYz Background - early results: “MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results http://bit.ly/1pdqkBR
	Pembrolizumab (pd-1 antibody - immune checkpoint inhibitor) for Advanced Primary Mediastinal Large B-cell Lymphoma http://1.usa.gov/1NP8ANc Testing Pembrolizumab (pd1 antibody) with R-CHOP for Previously Untreated DLBC Lymphoma -http://1.usa.gov/1V988b2
	Palbociclib studies for lymphoma or CLL ClinicalTrials.gov Find Trials
	RP6530 (dual PI3K inhib) ClinicalTrials.gov Find trials
	Procaspase Activating Compound-1 (PAC-1) in Advanced Malignancies - lymphoma -- ClinicalTrials.gov http://1.usa.gov/1zXsWvV Background: Cell Death Dis. 2013 Dec; 4(12): e968. Procaspase-activating compound-1 (PAC-1) a direct caspase-activating compound” http://1.usa.gov/1zp1pTi
	PNT2258 (first-in-class DNAi ) for Pretreated Diffuse Large B-Cell Lymphoma (Wolverine) http://1.usa.gov/1x2Yy2I ASH 2013: Paper: The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma http://bit.ly/1q4tvPp * Full text: A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors http://1.usa.gov/Z53YLF
	Selinexor (KPT-330) lymphoma trial query - ClinicalTrials.gov http://1.usa.gov/1xs0cJv ASH 2014: The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)
	TGR-1202, PI3K Delta Inhibitor in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients” http://1.usa.gov/1lBvVC8 Rationale: ASH Paper: - PI3K-δ Inhibitor TGR-1202 With Brentuximab Vedotin Synergistically Induces G2/M Phase Arrest and Cell Death In Hodgkin Cell Lines http://bit.ly/1qppOEu

====

	Bispecific EGFR-cMet antibody , JNJ-64052781, for Relapsed or Refractory B-cell Malignancies http://1.usa.gov/1MGhnNf  (very early, no lymphoma-specific background found so far)
	ASCO Post: “Novel Agents Show Activity in relapsed Non-Hodgkin Lymphoma” including CRs http://bit.ly/1dSn1gv Promising reports in this article - impressive outcomes - particularly for single agents in relapse setting.

Locate
Studies on
ClinicalTrials.gov
 

Monoclonal antibodies (Mab)
  See also Immune mediated

Monoclonal antibodies (MAbs) are proteins generated in labs by humans ... that bind to one (mono) antigen.  MAbs are similar to the proteins made by the immune system (by b-cells) to combat infections. 

MAbs are generally given into a vein.  the proteins then circulate in the blood and lymph system until binding to a specific target.  Once engaged with the antigen (as a key fits a lock) the MAbs can directly or indirectly lead to the death of the cell or block a process contributing to the growth or persistence of the lymphoma cells. 

CD20 MAbs such as Rituxan, for example, can lead to cell death directly or lead to immune-mediated killing of the engaged cells.  MAbs can also be used to deliver radiation or toxins in a more targeted way  -- only to the cells that have the target on the cell surface, such as only to mature b-cells.  See also antibody-drug conjugate and radioimmunotherapy.

 
 
Agent name or class

Click on name or class
to search for background
 

Count

click > to see current click count

 
cd4 antibodies

Zanolimumab | List studies - ClinicalTrials.gov  (0 open studies for t-cell lymphoma as of 6/22) | >  66 clicks

 

 
CD19 antibodies

List studies - ClinicalTrials.gov (42 studies for this class of agent as of 6/18)  | >  (26 clicks)

Note:  The studies listed on ClinicalTrials.gov for cd19 antibodies may include different classes of agents that make use of cd19 as a target, such as t-cells modified to act like antibodies (CART 19).  Also see antibody-drug conjugate or radioimmunotherapy.
 

	MEDI-551 ( cd19 antibody, humanized)   List studies - ClinicalTrials.gov  (3 studies as of 6/18) | >  (68 clicks)
	XmAb5574 / MOR00208  List studies - ClinicalTrials.gov  (2 studies as of 6/18)  >  (13 clicks)

CD20 antibodies

List studies - ClinicalTrials.gov (87 open studies) |  > (Click count: New)

This class of antibody binds to the cd20 b-cell receptor.  The studies listed on ClinicalTrials.gov may include different classes of agents that make use of cd20 as a target, such as cd20 with a radiotherapy agent or toxin attached.  See antibody-drug conjugate or radioimmunotherapy.
 

	Arzerra ® (Ofatumumab) List studies - ClinicalTrials.gov (86 studies as of 6/18)  | >  (210 clicks)
	GA-101 (Obinutuzumab)   List studies - ClinicalTrials.gov  (33 studies as of 6/18) >  (453 clicks)
	Rituxan ® (Rituximab / Mabthera) List studies - ClinicalTrials.gov | 85 studies as of 6/18 | > (85 clicks)
	Ublituximab List studies - ClinicalTrials.gov  (2 studies as of 6/18) |  >  (453 clicks)
	Veltuzumab / Immu-106 / Ha20 List studies - ClinicalTrials.gov  (1 study open as of 6/18)  >  (modified link)

 
cd22 antibodies

List studies - ClinicalTrials.gov (10 open studies) |  > (Click count: New for class)

This antibody binds to the cd22 b-cell receptor.  The studies listed on ClinicalTrials.gov may include different classes of agents that make use of cd22 as a target, such as cd22 with a radiotherapy agent or a toxin attached.   See antibody-drug conjugate or radioimmunotherapy.
 

Epratuzumab List studies - ClinicalTrials.gov  (2 open studies as of 6/18)  | >  94 clicks Antibody-drug conjugates for this target: Inotuzumab Ozogamicin  (CD22 + calicheamicin) Find trials   > (214 clicks)   DCDT2980S  anti-CD22, conjugated to MMAE List studies - ClinicalTrials.gov  > (22 clicks)

 
cd23 antibodies

Lumiliximab (anti-cd23) List studies - ClinicalTrials.gov  (0 open, 3 completed studies)  >  (48 clicks)

 
cd30 antibodies

List studies - ClinicalTrials.gov  (new query for this class)
 

SGN-30 List studies - ClinicalTrials.gov  (48 open studies as of 6/19) | >  (61 clicks)

Antibody-drug conjugates for this target:

Adcetris ®  cd30 antibody-drug conjugate (SGN-35 / brentuximab vedotin)  cd30 + antitubulin  List studies - ClinicalTrials.gov  (48 open studies as of 6/19) |  >  > ( updated query - 236 clicks)

 
cd37 antibodies

TRU-016 (Otlertuzumab)  List studies - ClinicalTrials.gov (1 open study as of 6/22) | >   (115 clicks)

 
cd38 antibodies

Daratumumab List studies - ClinicalTrials.gov  (1 open study as of 6/22) | >  (5 clicks) Daratumumab (immune-modulating antibody - targeting cell surface receptor cd38) A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of daratumumab to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells. Preclinical report: Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of CLL and B-Cell Non–Hodgkin Lymphoma http://bit.ly/1coqc22

 
cd39 antibodies

 No studies at this time (7/14).  This class of antibody potentially blocking tumor-mediated immunosuppression.
 

 
Campath ® (alemtuzumab)

 

 >

  
MDX-1411
 

 

>

 
Milatuzumab / hLL1
  
 

 >

 
IMMU-114 (anti-HLA-DR)

  
 

 >

  
Mogamulizumab
Mogo / KW-0761 / AMG-761

PAL
 

>

Bispecific antibodies

Binding two receptors expressed on tumor cells and/or other immune cells
 

Agent name or class

Find Trials

  
DT2219ARL

Bispecific antibody with immunotoxin

  

>   >

 
Blinatumomab / MT103 / BiTe)
 
 

>

antibody-drug conjugates

Antibodies that deliver toxins to extracellular (CD) targets on tumor cells

Reports by class
 

Agent name or class

Find Trials

  
SGN-CD19A
anti-CD19 + toxin

 

>

 
 
SAR3419
anti-CD19 + maytansinoi
 
  

>

Polatuzumab Vedotin

 
DT2219ARL
anti-CD19 & 22 antibody + immunotoxin

 

>

 
Inotuzumab Ozogamicin
anti-CD22 + calicheamicin
 

 

>

 
DCDT2980S
anti-CD22, conjugated to MMAE

 

>

 
LMB-2 immunotoxin
anti-CD25 antibody + immunotoxin
 

>

 
Adcetris ® 
(SGN-35 / brentuximab vedotin)
anti-cd30 + antitubulin

 

>

Radio-immunotherapy

Antibodies delivering radiation to tumor cells
 

 
Agent or class

Find Trials

 
Radioimmunotherapy  
 

 
Find trials
 

>

 
Betalutin 
(Lu-tetraxetan-tetulomab)
 
 

>

  
Bexxar ®
DISCONTINUED by GSK
 

>

  
Zevalin ®
anti-CD20 + Yttrium 90
(Ibritumomab tiuxetan)
 
 

>

   
epratuzumab tetraxetan
anti-CD22 with fractionated Yttrium 90 
 
 

>

Immune-mediated

Immune mediated therapy assists in helping the immune system to attack the tumor.

See also antibody agents, and radioimmunotherapy
 

 

Agent or class

Find Trials

 
 Anti-PD-1 antibody

   Pidilizumab (CT-011)

    Lambrolizumab (nivolumab)

    Pembrolizumab 

    MPDL3280A
  
(Immune checkpoint blockade)

Reports

>   >   >   >

 
Ipilimumab

anti-CTL-A (MXD-010)

(Immune checkpoint blockade)

Find trials

>

 Immunocytokine therapy

Two immune components – antibodies and cytokines

CC-122 

(immune modulating / cereblon)

 
Revlimid ® / Lenalidomide / CC 5013

(Immune modulating / cereblon)
 

>

Lenalidomide AND Rituxan

 >
 

 Pomalidomide  (Immune modulating)

>
 

 
 T-cell therapy (adoptive immunotherapy)
 

>

 
cd19 CAR T-cell therapy

CAR - chimeric antigen receptor / adoptive immunotherapy  PAL

 >  > | >

Vaccine

 >
 

Cytotoxic Agents

Damage the DNA of rapidly dividing cells, triggering apoptosis (programmed cell death)
 

 
Agent

Find Trials

 
Treanda ®

(Bendamustine)  
 
 

>

 
Bendamustine
phase 3 trials
 

>

 
Folotyn ® (Pralatrexate)
 

>

 
Pixantrone
 

Request:  Open Studies >
   

Reports

>

Targeted Agents

Epigenetic Agents

Agents that modify gene expression (by methylation or acetylation of histones and other elements) can reprogram how tumor cells behave: grow, die, or differentiate by activating or turning on genes.

DNA methylation

can reactivate tumor suppressor genes by altering methylation

Hypermethylation-associated silencing of tumor suppressor genes has been shown to occur in lymphoid/hematopoietic malignancies, disrupting many cellular pathways.1-3 Unlike genetic alterations in cancer, hypermethylation changes are potentially reversible by pharmacologic inhibition of DNA methylation.4 The cytidine analogs 5-aza-2′-deoxycytidine and 5-azacytidine are capable of reactivating tumor suppressor genes that were silenced by hypermethylation.4

Agent

Find Trials

 
Vidaza ®
 
(5-Azacytidine)
 
 

>  >

HDAC inhibition

 
Agent

Find Trials

 
Abexinostat (PCI-24781)
 
 

 >

 
Belinostat (PXD101)
 
 

 >

 

Results of the Pivotal Phase II BELIEF Study

Mocetinostat

 
Panobinostat (LBH589)
 
 

  >

 
Romidepsin ® (Depsipeptide)
 
 

 > 

 
Valproic acid
 
 

  >

 
Zolinza ® (Vorinostat)
 
 

 >

Apoptosis activation

Agent

Find Trials

 
ABT-199  (Venetoclax)
 
 

Find trials

 >

ASCO report
 

PNT2258

Procaspase Activating Compound-1 (PAC-1)

Obatoclax mesylate
(GX15-070)
 
 

-

>
 

mTOR

 
Agent

Find Trials

CC-223

dual mTOR inhibitor (oral)

>
 

Everolimus / RAD001

>

Leukemia report
   

Temsirolimus / CCI-779 

 
Kinase inhibitors

Inhibit pathways that are overactive in cancer cells
 

 
     B-cell Receptor pathway
 

 
Target
 

AVL-292
 
 

>
 

ACP-196

 
Idelalisib / GS-1101 / CAL101

 
 

 >
 

Ibrutinib (PCI-32765) 

 
 

>
 

Ibrutinib - CLL studies
 

 
Ibrutinib - lymphoma studies
 

 
IPI-145 (Duvelisib)
 
 

>  >
 

Alisertib (MLN8237)
  
 

>
 
Also http://bit.ly/18sChgG
 

Activating tumor suppressor gene
 

APTO-253 (LOR-253)

Selinexor (KPT-330)
 

Other targeted agents

 

	ACY-1215 (Ricolinostat) HDAC6 inhibitor Acetylon Announces Preclinical Data of ACY-1215 for the Treatment of Lymphoma Highlighted at 12th International Conference on Malignant Lymphoma (ICML) | Business Wire http://bit.ly/1hDNjBL  * List Results -  ClinicalTrials.gov
	AEB071 (Sotrastaurin) PKC inhibitor   | AACR report * List results - ClinicalTrials.gov  >
	AZD6738 orally bio-available inhibitor of ataxia telangiectasia and rad3 related (ATR), a key serine/threonine protein kinase involved in DNA damage response signaling caused by DNA replication associated stress.   * First Time in Patient Multiple Ascending Dose Study http://1.usa.gov/19TnU1m
	Copanilisib (BAY 80-6946) An intravenously administered compound that has significant activity against alpha and delta isoforms of PI3K; the delta isoform has a role in B-cell signaling, development     * List results -  ClinicalTrials.gov
	CPI-0610 A small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins * A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma http://1.usa.gov/15MC83D
	Crizotinib anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, * List results - ClinicalTrials.gov
	Entospletinib  (GS-9973) Oral, selective inhibitor of spleen tyrosine kinase (Syk) Dr Sharman's Blog 2015: Syk not Sick http://bit.ly/1z5fvVz  Dr Sharman discusses yet another pathway targeting drug: "Entospletinib looks to have pretty good efficacy in CLL. It is a twice daily pill. You really cannot compare across studies, but some of the early numbers look a lot like idelalisib. Lots of work left to be done and the trial is still recruiting patients with CLL (trial link here). Talk to your own doctor or seek an opinion at one of the centers offering the trial." * List results - ClinicalTrials.gov
	ISIS 481464 (AZD9150) antisense oligonucleotide inhibitor of STAT3 * List results - ClinicalTrials.gov   >
	ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas http://bit.ly/1HtPIya * Dose-finding safety Study of Oral ONC201 in relapsed Non-Hodgkin's Lymphoma - ClinicalTrials.gov
	PD 0332991 (palbociclib) cyclin-dependent kinase (CDK) 4/6–specific inhibitor  | Reports * List results ClinicalTrials.gov  >
	PF-05082566   an anti-CD-137 agonist antibody that is designed to help the immune system go after the lymphoma cells with Rituxan attached to them." * CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies http://bit.ly/1aXT0cB  * Study of PF-05082566 as single Agent And In Combination With Rituximab  http://1.usa.gov/1b6LCby
	PNT2258 DNAi molecule targets the non-coding, non-transcribed regulatory region of the Bcl2 gene. *   List Results - ClinicalTrials.gov
	proteasome inhibitors MLN970 / Bortezomib /  Velcade ® , Carfilzomib,  CEP 18770  * List trials - ClinicalTrials.gov
	Ruxolitinib   Janus Kinases (JAK) inhibitor Related Citations for PubMed (Select 22869151) - PubMed - NCBI Background on this drug for other indications: wikipedia.org * Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma - Full Text View - ClinicalTrials.gov  * List results - ClinicalTrials.gov
	SAR245409 (Voxtalisib) An oral pan-inhibitor of PI3K and mTOR  * List Results - ClinicalTrials.gov
	SAR245408 Pan- PI3K inhibitor * A Study of the Safety and Pharmacokinetics in Patients With Solid Tumors or Lymphoma - http://1.usa.gov/1d6jTxS
	YM155 Survivin kinase inhibitor  * Reports * List results ClinicalTrials.gov  >  61 looks

 
Discontinued agents
 

 
Enzastaurin
 

>

Navitoclax / ABT-263 >
 
Discontinued due to improvement in safety with ABT-199 above
 

TL32711 (birinapant)

Reports
* Search results ClinicalTrials.gov  >